Merck's PCSK9 pill holds 'significant advantage' with injectable-like cholesterol reductions: analysts

fiercebiotech.com/biotech/merck-pcsk9-pill-holds-significant-advantage-injectable-cholesterol-lowering-analysts

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables.
The results from two phase 3 trials give Merck’s once-daily drug, enlicitide, a “significant advantage” over…

This story appeared on fiercebiotech.com, 2025-11-10 23:51:22.070000.
The Entire Business World on a Single Page. Free to Use →